Nanjing Hicin Pharmaceutical Co., Ltd. Class A

Nanjing Hicin Pharmaceutical Co., Ltd. Class A

SSZSE:300584
28.30
CNY
-0.89
(-3.05%)
0.64EPS
52.23P/E
3.74BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Nanjing Hicin Pharmaceutical Co., Ltd. Class A carries a market capitalization of 3.74B, placing it among publicly traded companies globally. Its enterprise value stands at 4.03B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.74B
Enterprise Value4.03B

Share Statistics

As of September 30, 2026, Nanjing Hicin Pharmaceutical Co., Ltd. Class A has 120.00M shares outstanding.

Shares Outstanding120.00M

Valuation Ratios

As of September 30, 2026, Nanjing Hicin Pharmaceutical Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 52.23. The price-to-sales ratio is 4.59, and the price-to-book ratio stands at 3.43.

PE Ratio52.23
PS Ratio4.59
PB Ratio3.43
P/TBV Ratio3.81

Enterprise Valuation

As of September 30, 2026, Nanjing Hicin Pharmaceutical Co., Ltd. Class A trades at an EV/EBITDA multiple of 36.15 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.95 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 36.15 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 4.03B versus a market cap of 3.74B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales4.95
EV / EBITDA36.15
EV / EBIT36.15

Financial Position

As of September 30, 2026, Nanjing Hicin Pharmaceutical Co., Ltd. Class A maintains a current ratio of 1.12, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 29.71, indicating elevated leverage, while an interest coverage ratio of 18.90 demonstrates strong ability to service its debt obligations.

Current Ratio1.12
Quick Ratio0.08
Debt / Equity29.71
Debt / EBITDA2.91
Interest Coverage18.90

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Nanjing Hicin Pharmaceutical Co., Ltd. Class A posted a return on equity (ROE) of 6.72, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 5.79 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.68, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.12, useful for judging operating efficiency across full business cycles. The company generates approximately 1.47M in revenue per employee across its workforce of 553.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.78 indicates how many times Nanjing Hicin Pharmaceutical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)6.72
Return on Assets (ROA)4.68
Return on Invested Capital (ROIC)5.79
Return on Capital Employed (ROCE)5.12
Revenue Per Employee1.47M
Employee Count553.00
Inventory Turnover2.78

Taxes

CNY

Over the twelve months ended September 30, 2026, Nanjing Hicin Pharmaceutical Co., Ltd. Class A recorded 28.12M in income tax expense. That works out to an effective tax rate of 26.89, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 104.57M, leaving 71.64M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax28.12M
Effective Tax Rate26.89

Stock Price Statistics

CNY

As of the close on November 17, 2026, Nanjing Hicin Pharmaceutical Co., Ltd. Class A's stock has declined approximately 59.07% over the past 52 weeks. The 50-day moving average sits at 30.89, while the 200-day moving average is 37.03.

52-Week Price Change-59.07%
50-Day Moving Average30.89
200-Day Moving Average37.03

Income Statement

CNY

Over the twelve months ended September 30, 2026, Nanjing Hicin Pharmaceutical Co., Ltd. Class A generated 814.80M in revenue and converted that into 71.64M in net income, yielding earnings per share of 0.64. EBITDA reached 111.53M, while operating income came in at 152.38M.

Revenue814.80M
Gross Profit583.89M
Operating Income152.38M
Pretax Income104.57M
Net Income71.64M
EBITDA111.53M
EBIT111.53M
Earnings Per Share (EPS)0.64

Balance Sheet

CNY

As of September 30, 2026, Nanjing Hicin Pharmaceutical Co., Ltd. Class A holds 33.38M in cash and equivalents against 324.24M in total debt, resulting in a net debt position of 264.12M. Total book value stands at 1.09B, with working capital of 49.44M providing operational flexibility.

Cash & Cash Equivalents33.38M
Total Debt324.24M
Net Debt264.12M
Equity (Book Value)1.09B
Book Value Per Share9.09
Working Capital49.44M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-28.94M

Margins

Over the twelve months ended September 30, 2026, Nanjing Hicin Pharmaceutical Co., Ltd. Class A posted a gross margin of 71.66, reflecting its pricing power and cost economics. The operating margin of 18.70 and net profit margin of 8.79 provide insight into operational efficiency.

Gross Margin71.66
Operating Margin18.70
Pretax Margin12.83
Profit Margin8.79
EBITDA Margin13.69

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Nanjing Hicin Pharmaceutical Co., Ltd. Class A paid dividends of 0.16 per share. The dividend payout ratio of 23.37 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 0.39, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Nanjing Hicin Pharmaceutical Co., Ltd. Class A shareholders.

Dividend Per Share0.16
Payout Ratio23.37
Shareholder Yield0.39

Stock Splits

Nanjing Hicin Pharmaceutical Co., Ltd. Class A's most recent stock split took place on April 20, 2018 with a 2:3 split ratio.

Last Split Date4/20/2018
Split Ratio2:3

Scores

As of September 30, 2026, Nanjing Hicin Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 6.20, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score6.20